These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Fargnoli et al_v2.pdf (843.04 kB)
New L-proline uptake inhibitors with anti-Trypanosoma cruzi activity
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
revised on 03.12.2019 and posted on 11.12.2019by Lucia Fargnoli, Esteban A. Panozzo-Zénere, Lucas Pagura, María Julia Barisón, Julia A. Cricco, Ariel Mariano Silber, Guillermo Labadie
is an important amino acid for the pathogenic protists belonging to Trypanosoma
and Leishmania genera. In Trypanosoma cruzi, the etiological
agent of Chagas disease, this amino acid is involved in fundamental biological
processes such as ATP production, differentiation of the insect and
intracellular stages, the host cell infection and the resistance to a variety
of stresses, including nutritional and osmotic as well as oxidative imbalance.
In this study, we explore the L-Proline uptake as a chemotherapeutic target for
T. cruzi. For this, we propose a novel rational to design inhibitors
containing this amino acid as a recognizable motif. This rational consists of
conjugating the amino acid (proline in this case) to a linker and a variable
region able to block the transporter. We obtained a series of sixteen 1,2,3-triazolyl-proline
derivatives through alkylation and copper(I)-catalyzed azide-alkyne cycloaddition
(click chemistry) for in vitro screening against T. cruzi epimastigotes,
trypanocidal activity and proline uptake. We successfully obtained inhibitors
that are able to interfere with the amino acid uptake, which validated the
first example of a rationally designed chemotherapeutic agent targeting a
metabolite's transport. Additionally, we designed and prepared fluorescent
analogues of the inhibitors that were successfully taken up by T. cruzi, allowing following up their intracellular
fate. In conclusion, we successfully designed and produced a series of
metabolite uptake inhibitors. This is one of few examples of rationally designed
amino acid transporter inhibitor, being the first case where the strategy is
applied on the development of chemotherapy against Chagas disease. This
unprecedented development is remarkable having in mind that only a small
percent of the metabolite transporters has been studied at the structural
and/or molecular level.